Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
September 21, 2023 08:30 ET
|
Genprex, Inc.
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted...
Coave Therapeutics Appoints Genetic Medicine Expert Lolita Petit, PhD as Chief Scientific Officer
September 21, 2023 06:00 ET
|
Coave Therapeutics
Paris, France, September 21, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023 08:00 ET
|
Ocugen
MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
September 19, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Regenerative Medicine Market Size is projected to reach USD 72.2 Billion by 2030, growing at a CAGR of 17.6%: Straits Research
September 18, 2023 11:20 ET
|
Straits Research
New York, United States, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Regenerative drugs are used to repair, swap out, and regenerate tissues and organs harmed by injury, disease, or normal aging. Cell...
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
September 14, 2023 12:00 ET
|
Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...
AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders
September 14, 2023 03:00 ET
|
Alveogene
New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK...
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023 08:15 ET
|
Ocugen
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity...
Culture Biosciences Appoints Darcy Birse as Chief Commercial Officer
September 13, 2023 06:53 ET
|
Culture Biosciences
South San Francisco, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences, a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy...
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12, 2023 19:30 ET
|
Ocugen
MALVERN, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...